User Login

Back Medical Board of Advisors
  • Lawrence D. Piro, M.D.
    Clinician, Researcher & Lecturer
    International Expert in Hematologic Malignancies
    The Angeles Clinic and Research Institute
Dr. Piro is an internationally recognized expert in the hematologic malignancies, leukemia and lymphoma. As clinician, researcher, and lecturer, he has dedicated his career to the discovery of novel therapeutics to combat these aggressive malignancies. Through his work, major advances have been made in the treatment of patients worldwide. Today, Dr. Piro lectures around the world on various topics in cancer and cancer research in addition to continuing a robust clinical practice. He has received his Medical Degree from the Washington University School of Medicine and completed post-graduate training at Barnes Hospital and Washington University. Before joining The Angeles Clinic and Research Institute, he served as Head of the Division of Hematology and Oncology, and the Director of the Ida M. and Cecil H. Green Center at Scripps Clinic, San Diego, California. Dr. Piro's medical career began in the study of non-Hodgkin's lymphoma. His paper in the New England Journal of Medicine identified that the treatment of hairy-cell leukemia with a single course of Leustatin produced complete remission in 90 percent of patients and led to its FDA approval. His dedication to lymphoma research continued with work on pivotal trials on first monoclonal antibody to ever be approved for treatment of cancer, Rituxan ®, which revolutionized the treatment of low-grade lymphoma. The study demonstrated a higher response rate with 8 weekly doses of Rituxan and resulted in the FDA approval of the 8 weekly dose regimen.

Dr. Piro serves on a multitude of regional and national committees on leukemia and lymphoma. His research most recently has been in the development of individualized cancer therapy including novel imaging techniques to identify targets susceptible to drug treatment and radio-immunotherapy.